Skip to main content

Table 2 The association between XRCC1 Arg194Trp and Arg399Gln polymorphisms and objective response, OS and PFS

From: Association between the XRCC1 polymorphisms and clinical outcomes of advanced NSCLC treated with platinum-based chemotherapy: a meta-analysis based on the PRISMA statement

XRCC1 Objective response Overall survival Progression-free survival
Studies(refs.) Pooled OR Ph /I 2(%) Studies(refs.) Pooled HR Ph /I 2(%) Studies(refs.) Pooled HR Ph /I 2(%)
Arg194Trp
 ArgArg vs. TrpTrp
  All 7 [13–16, 23, 26, 27] 0.64(0.44-0.91) 0.19/31.1 3 [23, 26, 31] 1.19(0.73–1.65) 0.92/0.0 3 [23, 26, 31] 1.28(0.74–1.82) 0.92/0.0
  Sample size>100 6 [13–16, 23, 26] 0.67(0.46-0.97) 0.17/35.4 3 [23, 26, 31] 1.19(0.73–1.65) 0.92/0.0 3 [23, 26, 31] 1.28(0.74–1.82) 0.92/0.0
  Year ≥ 2009 5 [13, 14, 23, 26, 27] 0.65(0.44-0.99) 0.09/49.8 3 [23, 26, 31] 1.19(0.73–1.65) 0.92/0.0 3 [23, 26, 31] 1.28(0.74–1.82) 0.92/0.0
 TrpArg vs. TrpTrp
  All 7 [13–16, 23, 26, 27] 1.05(0.73–1.51) 0.35/10.8 - - - - - -
  Sample size>100 6 [13–16, 23, 26] 1.04(0.71–1.52) 0.24/25.4 - - - - - -
  Year ≥ 2009 5 [13, 14, 23, 26, 27] 0.91(0.60–1.39) 0.56/0.0 - - - - - -
 ArgArg + TrpArg vs. TrpTrp
  All 7 [13–16, 23, 26, 27] 0.79(0.56–1.11) 0.32/13.9 1 [26] - - 1 [26] - -
  Sample size>100 6 [13–16, 23, 26] 0.80(0.57–1.14) 0.23/27.1 1 ([26]) - - 1 [26] - -
  Year ≥ 2009 5 [13, 14, 23, 26, 27] 0.75(0.51–1.10) 0.26/24.6 1 ([26]) - - 1 [26] - -
 ArgArg vs. TrpArg + TrpTrp
  All 7 [13–16, 23, 26, 27] 0.55(0.36-0.84) 0.01/63.0 3 [23, 26, 31] 1.07(0.79–1.35) 0.79/0.0 3 [23, 26, 31] 0.94(0.72–1.17) 0.648/0.0
  Sample size>100 6 [13–16, 23, 26] 0.60(0.39-0.92) 0.02/62.7 3 [23, 26, 31] 1.07(0.79–1.35) 0.79/0.0 3 [23, 26, 31] 0.94(0.72–1.17) 0.648/0.0
  Year ≥ 2009 5 [13, 14, 23, 26, 27] 0.63(0.37–1.05) 0.02/65.9 3 [23, 26, 31] 1.07(0.79–1.35) 0.79/0.0 3 [23, 26, 31] 0.94(0.72–1.17) 0.648/0.0
Arg399Gln          
 GlnGln vs. ArgArg
  All 10 [13–15, 17, 20, 22–24, 26, 27] 0.77(0.38–1.57) 0.005/62.0 7 [17, 19, 22–24, 28, 31] 1.15(0.61–1.69) 0.006/66.6 5 [17, 22, 23, 26, 31] 0.72(0.48-0.97) 0.136/42.9
  Sample size>100 8 [13–15, 17, 22–24, 26] 0.77(0.35–1.73) 0.002/69.9 7 [17, 19, 22–24, 28, 31] 1.15(0.61–1.69) 0.006/66.6 5 [17, 22, 23, 26, 31] 0.72(0.48-0.97) 0.136/42.9
  Asian 9 [13–15, 17, 20, 23, 24, 26, 27] 0.75(0.33–1.68) 0.003/66.1 4 [17, 23, 24, 31] 0.86(0.41–1.30) 0.052/61.2 4 [17, 23, 26, 31] 0.67(0.40-0.94) 0.106/51.0
  Caucasian 1 [22] - - 3 [19, 22, 28] 2.29(1.25-3.33) 0.423/0.0 1 [22] - -
  Year ≥ 2009 9 [13, 14, 17, 22–24, 26, 27] 0.83(0.39–1.77) 0.005/63.5 6 [17, 19, 22–24, 31] 1.06(0.54–1.57) 0.011/66.2 5 [17, 22, 23, 26, 31] 0.72(0.48-0.97) 0.136/42.9
 GlnArg vs. ArgArg
  All 10 [13–15, 17, 20, 22–24, 26, 27] 0.90(0.67–1.21) 0.053/46.2 7 [17, 19, 23–25, 28, 31] 0.93(0.68–1.18) 0.003/69.3 4 [17, 23, 26, 31] 0.96(0.79–1.14) 0.416/0.0
  Sample size>100 8 [13–15, 17, 22–24, 26] 0.89(0.63–1.26) 0.02/57.8 7 [17, 19, 23–25, 28, 31] 0.93(0.68–1.18) 0.003/69.3 4 [17, 23, 26, 31] 0.96(0.79–1.14) 0.416/0.0
  Asian 9 [13–15, 17, 20, 23, 24, 26, 27] 0.90(0.65–1.25) 0.035/51.8 4 [17, 23, 24, 31] 0.91(0.56–1.27) 0.003/78.1 4 [17, 23, 26, 31] 0.96(0.79–1.14) 0.416/0.0
  Caucasian 1 [22] - - 3 [19, 25, 28] 1.01(0.51–1.51) 0.057/65.2 - - -
  Year ≥ 2009 9 [13, 14, 17, 22–24, 26, 27] 0.97(0.79–1.20) 0.112/38.4 5 [17, 19, 23, 24, 31] 0.97(0.64–1.31) 0.003/74.7 4 [17, 23, 26, 31] 0.96(0.79–1.14) 0.416/0.0
 GlnGln + GlnArg vs. ArgArg
  All 13 [13–15, 17–24, 26, 27] 0.72(0.50–1.04) 0.000/70.9 6 [17, 19, 20, 23, 26, 31] 0.73(0.50–1.05) 0.001/72.5 4 [17, 23, 26, 31] 0.94(0.77–1.10) 0.274/22.8
  Sample size>100 10 [13–15, 17, 19, 21–24, 26] 0.78(0.53–1.16) 0.000/72.5 5 [17, 19, 23, 26, 31] 0.85(0.55–1.15) 0.02/65.9 4 [17, 23, 26, 31] 0.94(0.77–1.10) 0.274/22.8
  Asian 11 [13–15, 17, 18, 20, 21, 23, 24, 26, 27] 0.70(0.46–1.07) 0.000/75.7 5 [17, 20, 23, 26, 31] 0.65(0.43-0.98) 0.003/71.7 4 [17, 23, 26, 31] 0.94(0.77–1.10) 0.274/22.8
  Caucasian 2 [19, 22] 0.82(0.46–1.44) 0.966/0.0 1 [19] - - - - -
  Year ≥ 2009 12 [13, 14, 17–24, 26, 27] 0.93(0.65–1.34) 0.004/64.3 6 [17, 19, 20, 23, 26, 31] 0.73(0.50–1.05) 0.001/72.5 4 [17, 23, 26, 31] 0.94(0.77–1.10) 0.274/22.8
 GlnGln vs. GlnArg + ArgArg
  All 12 [13–15, 17, 20, 22–24, 26, 27, 29, 30] 0.85(0.50–1.45) 0.028/49.0 5 [19, 24, 26, 29, 30] 1.19(0.53–1.84) 0.01/68.9 2 [26, 30] 0.94(0.37–1.52) 0.435/0.0
  Sample size>100 9 [13–15, 17, 22–24, 26, 29] 0.78(0.43–1.41) 0.015/58.0 4 [19, 24, 26, 29] 1.44(1.01-1.88) 0.686/0.0 1 [26] - -
  Asian 10 [13–15, 17, 20, 23, 24, 26, 27, 29] 0.75(0.41–1.37) 0.023/53.4 3 [24, 26, 29] 1.40(0.96–1.84) 0.999/0.0 1 [26] - -
  Caucasian 2 [22, 30] 1.58(0.42–5.98) 0.194/40.6 2 [19, 30] 1.43(−1.05–3.91) 0.058/72.1 1 [30] - -
  Year ≥ 2009 11 [13, 14, 17, 20, 22–24, 26, 27, 29, 30] 0.87(0.47–1.62) 0.038/51.0 5 [19, 24, 26, 29, 30] 1.19(0.53–1.84) 0.01/68.9 2 [26, 30] 0.94(0.37–1.52) 0.435/0.0
  1. Footnote: OR odds ratio, HR hazard ratio, refs references, OR/HR with the corresponding 95% CIs >/<1 means significance